Daniel Vigo1,2, Josep Maria Haro3, Irving Hwang4, Sergio Aguilar-Gaxiola5, Jordi Alonso6,7,8, Guilherme Borges9, Ronny Bruffaerts10, Jose Miguel Caldas-de-Almeida11, Giovanni de Girolamo12, Silvia Florescu13, Oye Gureje14, Elie Karam15,16,17, Georges Karam15,17, Viviane Kovess-Masfety18, Sing Lee19, Fernando Navarro-Mateu20, Akin Ojagbemi21, Jose Posada-Villa22, Nancy A Sampson4, Kate Scott23, Juan Carlos Stagnaro24, Margreet Ten Have25, Maria Carmen Viana26, Chi-Shin Wu27, Somnath Chatterji28, Pim Cuijpers29,30, Graham Thornicroft31, Ronald C Kessler4. 1. Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada. 2. Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA. 3. Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain. 4. Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA. 5. Center for Reducing Health Disparities, UC Davis Health System, Sacramento, California, USA. 6. Health Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain. 7. CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 8. Pompeu Fabra University (UPF), Barcelona, Spain. 9. National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico. 10. Universitair Psychiatrisch Centrum - Katholieke Universiteit Leuven (UPC-KUL), Campus Gasthuisberg, Leuven, Belgium. 11. Lisbon Institute of Global Mental Health and Chronic Diseases Research Center (CEDOC), NOVA Medical School | Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal. 12. IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. 13. National School of Public Health, Management and Development, Bucharest, Romania. 14. Department of Psychiatry, University College Hospital, Ibadan, Nigeria. 15. Department of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University, Beirut, Lebanon. 16. Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Beirut, Lebanon. 17. Institute for Development, Research, Advocacy and Applied Care (IDRAAC), Beirut, Lebanon. 18. Ecole des Hautes Etudes en Santé Publique (EHESP), EA 4057, Paris Descartes University, Paris, France. 19. Department of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong. 20. UDIF-SM, Subdirección General de Planificación, Innovación y Cronicidad, Servicio Murciano de Salud, IMIB-Arrixaca, CIBERESP-Murcia, Murcia, Spain. 21. Department of Psychiatry, University of Ibadan, Nigeria. 22. Colegio Mayor de Cundinamarca University, Faculty of Social Sciences, Bogota, Colombia. 23. Department of Psychological Medicine, University of Otago, Dunedin, Otago, New Zealand. 24. Departamento de Psiquiatría y Salud Mental, Facultad de Medicina, Universidad de Buenos Aires, Argentina. 25. Trimbos-Instituut, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands. 26. Department of Social Medicine, Postgraduate Program in Public Health, Federal University of Espírito Santo, Vitoria, Brazil. 27. Department of Psychiatry, National Taiwan University Hospital & College of Medicine, Taipei, Taiwan. 28. Department of Information, Evidence and Research, World Health Organization, Geneva, Switzerland. 29. Department of Clinical Psychology, VU University, Amsterdam, The Netherlands. 30. The Netherlands & EMGO Institute for Health and Care Research, VU University Medical Centre, Amsterdam, The Netherlands. 31. Centre for Global Mental Health, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Abstract
BACKGROUND: Major depressive disorder (MDD) is a leading cause of morbidity and mortality. Shortfalls in treatment quantity and quality are well-established, but the specific gaps in pharmacotherapy and psychotherapy are poorly understood. This paper analyzes the gap in treatment coverage for MDD and identifies critical bottlenecks. METHODS: Seventeen surveys were conducted across 15 countries by the World Health Organization-World Mental Health Surveys Initiative. Of 35 012 respondents, 3341 met DSM-IV criteria for 12-month MDD. The following components of effective treatment coverage were analyzed: (a) any mental health service utilization; (b) adequate pharmacotherapy; (c) adequate psychotherapy; and (d) adequate severity-specific combination of both. RESULTS: MDD prevalence was 4.8% (s.e., 0.2). A total of 41.8% (s.e., 1.1) received any mental health services, 23.2% (s.e., 1.5) of which was deemed effective. This 90% gap in effective treatment is due to lack of utilization (58%) and inadequate quality or adherence (32%). Critical bottlenecks are underutilization of psychotherapy (26 percentage-points reduction in coverage), underutilization of psychopharmacology (13-point reduction), inadequate physician monitoring (13-point reduction), and inadequate drug-type (10-point reduction). High-income countries double low-income countries in any mental health service utilization, adequate pharmacotherapy, adequate psychotherapy, and adequate combination of both. Severe cases are more likely than mild-moderate cases to receive either adequate pharmacotherapy or psychotherapy, but less likely to receive an adequate combination. CONCLUSIONS: Decision-makers need to increase the utilization and quality of pharmacotherapy and psychotherapy. Innovations such as telehealth for training and supervision plus non-specialist or community resources to deliver pharmacotherapy and psychotherapy could address these bottlenecks.
BACKGROUND: Major depressive disorder (MDD) is a leading cause of morbidity and mortality. Shortfalls in treatment quantity and quality are well-established, but the specific gaps in pharmacotherapy and psychotherapy are poorly understood. This paper analyzes the gap in treatment coverage for MDD and identifies critical bottlenecks. METHODS: Seventeen surveys were conducted across 15 countries by the World Health Organization-World Mental Health Surveys Initiative. Of 35 012 respondents, 3341 met DSM-IV criteria for 12-month MDD. The following components of effective treatment coverage were analyzed: (a) any mental health service utilization; (b) adequate pharmacotherapy; (c) adequate psychotherapy; and (d) adequate severity-specific combination of both. RESULTS: MDD prevalence was 4.8% (s.e., 0.2). A total of 41.8% (s.e., 1.1) received any mental health services, 23.2% (s.e., 1.5) of which was deemed effective. This 90% gap in effective treatment is due to lack of utilization (58%) and inadequate quality or adherence (32%). Critical bottlenecks are underutilization of psychotherapy (26 percentage-points reduction in coverage), underutilization of psychopharmacology (13-point reduction), inadequate physician monitoring (13-point reduction), and inadequate drug-type (10-point reduction). High-income countries double low-income countries in any mental health service utilization, adequate pharmacotherapy, adequate psychotherapy, and adequate combination of both. Severe cases are more likely than mild-moderate cases to receive either adequate pharmacotherapy or psychotherapy, but less likely to receive an adequate combination. CONCLUSIONS: Decision-makers need to increase the utilization and quality of pharmacotherapy and psychotherapy. Innovations such as telehealth for training and supervision plus non-specialist or community resources to deliver pharmacotherapy and psychotherapy could address these bottlenecks.
Entities:
Keywords:
Effective coverage; major depressive disorder; pharmacotherapy; psychotherapy; treatment
Authors: Sagar V Parikh; Lena C Quilty; Paula Ravitz; Michael Rosenbluth; Barbara Pavlova; Sophie Grigoriadis; Vytas Velyvis; Sidney H Kennedy; Raymond W Lam; Glenda M MacQueen; Roumen V Milev; Arun V Ravindran; Rudolf Uher Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: Josep Maria Haro; Saena Arbabzadeh-Bouchez; Traolach S Brugha; Giovanni de Girolamo; Margaret E Guyer; Robert Jin; Jean Pierre Lepine; Fausto Mazzi; Blanca Reneses; Gemma Vilagut; Nancy A Sampson; Ronald C Kessler Journal: Int J Methods Psychiatr Res Date: 2006 Impact factor: 4.035
Authors: Philip S Wang; Sergio Aguilar-Gaxiola; Jordi Alonso; Matthias C Angermeyer; Guilherme Borges; Evelyn J Bromet; Ronny Bruffaerts; Giovanni de Girolamo; Ron de Graaf; Oye Gureje; Josep Maria Haro; Elie G Karam; Ronald C Kessler; Viviane Kovess; Michael C Lane; Sing Lee; Daphna Levinson; Yutaka Ono; Maria Petukhova; José Posada-Villa; Soraya Seedat; J Elisabeth Wells Journal: Lancet Date: 2007-09-08 Impact factor: 79.321
Authors: Koen Demyttenaere; Ronny Bruffaerts; Jose Posada-Villa; Isabelle Gasquet; Viviane Kovess; Jean Pierre Lepine; Matthias C Angermeyer; Sebastian Bernert; Giovanni de Girolamo; Pierluigi Morosini; Gabriella Polidori; Takehiko Kikkawa; Norito Kawakami; Yutaka Ono; Tadashi Takeshima; Hidenori Uda; Elie G Karam; John A Fayyad; Aimee N Karam; Zeina N Mneimneh; Maria Elena Medina-Mora; Guilherme Borges; Carmen Lara; Ron de Graaf; Johan Ormel; Oye Gureje; Yucun Shen; Yueqin Huang; Mingyuan Zhang; Jordi Alonso; Josep Maria Haro; Gemma Vilagut; Evelyn J Bromet; Semyon Gluzman; Charles Webb; Ronald C Kessler; Kathleen R Merikangas; James C Anthony; Michael R Von Korff; Philip S Wang; Traolach S Brugha; Sergio Aguilar-Gaxiola; Sing Lee; Steven Heeringa; Beth-Ellen Pennell; Alan M Zaslavsky; T Bedirhan Ustun; Somnath Chatterji Journal: JAMA Date: 2004-06-02 Impact factor: 56.272
Authors: Graham Thornicroft; Somnath Chatterji; Sara Evans-Lacko; Michael Gruber; Nancy Sampson; Sergio Aguilar-Gaxiola; Ali Al-Hamzawi; Jordi Alonso; Laura Andrade; Guilherme Borges; Ronny Bruffaerts; Brendan Bunting; Jose Miguel Caldas de Almeida; Silvia Florescu; Giovanni de Girolamo; Oye Gureje; Josep Maria Haro; Yanling He; Hristo Hinkov; Elie Karam; Norito Kawakami; Sing Lee; Fernando Navarro-Mateu; Marina Piazza; Jose Posada-Villa; Yolanda Torres de Galvis; Ronald C Kessler Journal: Br J Psychiatry Date: 2016-12-01 Impact factor: 9.319
Authors: David M Clark; Lauren Canvin; John Green; Richard Layard; Stephen Pilling; Magdalena Janecka Journal: Lancet Date: 2017-12-07 Impact factor: 79.321
Authors: Dan J Stein; Steven J Shoptaw; Daniel V Vigo; Crick Lund; Pim Cuijpers; Jason Bantjes; Norman Sartorius; Mario Maj Journal: World Psychiatry Date: 2022-10 Impact factor: 79.683
Authors: Daniel V Vigo; Alan E Kazdin; Nancy A Sampson; Irving Hwang; Jordi Alonso; Laura Helena Andrade; Olatunde Ayinde; Guilherme Borges; Ronny Bruffaerts; Brendan Bunting; Giovanni de Girolamo; Silvia Florescu; Oye Gureje; Josep Maria Haro; Meredith G Harris; Elie G Karam; Georges Karam; Viviane Kovess-Masfety; Sing Lee; Fernando Navarro-Mateu; José Posada-Villa; Kate Scott; Juan Carlos Stagnaro; Margreet Ten Have; Chi-Shin Wu; Miguel Xavier; Ronald C Kessler Journal: Int J Ment Health Syst Date: 2022-06-23
Authors: Meredith G Harris; Alan E Kazdin; Richard J Munthali; Daniel V Vigo; Irving Hwang; Nancy A Sampson; Ali Al-Hamzawi; Jordi Alonso; Laura Helena Andrade; Guilherme Borges; Brendan Bunting; Silvia Florescu; Oye Gureje; Elie G Karam; Sing Lee; Fernando Navarro-Mateu; Daisuke Nishi; Charlene Rapsey; Kate M Scott; Juan Carlos Stagnaro; Maria Carmen Viana; Bogdan Wojtyniak; Miguel Xavier; Ronald C Kessler Journal: Int J Ment Health Syst Date: 2022-01-29
Authors: Brian Rush; Olivia Marcus; Sara García; Anja Loizaga-Velder; Gabriel Loewinger; Ariane Spitalier; Fernando Mendive Journal: Front Pharmacol Date: 2021-05-19 Impact factor: 5.810